摘要
Comment on ‘Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials’, which was published in The Lancet, https://doi.org/10.1016/S0140-6736(23)00215-5. This collaborative analysis of patients with—or at high risk of—atherosclerotic cardiovascular disease (ASCVD), who were receiving contemporary statin treatment and were participants in three large randomized trials, evaluated the importance of high-sensitivity C-reactive protein (hs-CRP, a biomarker of residual inflammatory risk) and LDL-cholesterol (LDL-C, a biomarker of residual cholesterol risk) levels as predictors of future major adverse cardiovascular events (MACEs), cardiovascular death, and all-cause death.1 Hazard ratios (HRs) for cardiovascular events and deaths were calculated across quartiles of hs-CRP and LDL-C in analyses adjusted for age, gender, body mass index (BMI), smoking status, blood pressure, previous history of cardiovascular disease, and randomized treatment group assignment. Among the 31 245 patients included in the analysis from the Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) (n = 9988), A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (REDUCE-IT) (n = 8179), and Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH) (n = 13 078) trials (mean age from 63 to 64 years, percentage of women from 29% to 35%, mean follow-up from 3 to 5 years), the percentage on a high-intensity statin (atorvastatin ≥40 mg once daily or rosuvastatin ≥20 mg once daily) ranged from 31% to 72%, across the three trials. The median baseline hs-CRP concentrations ranged from 2.1 mg/L to 2.3 mg/L and the median baseline LDL-C concentrations from 75 to 78 mg/dL. The quartile cut-points for both baseline hs-CRP and LDL-C were concordant across the three trials. The results were similar in each of the three trials separately and in the meta-analysis. Residual inflammatory risk, as measured by baseline hs-CRP, was significantly associated with incident MACEs [15.0% vs. 12.6%, highest hs-CRP quartile vs. lowest hs-CRP quartile; pooled adjusted HR 1.31, 95% confidence interval (CI) 1.20–1.43; P < 0.0001], cardiovascular mortality (5.4% vs. 2.1%; HR 2.68, 95% CI 2.22–3.23; P < 0·0001), and all-cause mortality (9.8% vs. 4.4%; HR 2.42, 95% CI 2.12–2.77; P < 0.0001). By contrast, the relationship of residual cholesterol risk was neutral for MACEs (13% vs. 13.6%, highest LDL-C quartile vs. lowest LDL-C quartile; pooled adjusted HR 1.07, 95% CI 0.98–1.17; P = 0.11), and of low magnitude for cardiovascular death (3.8% vs. 3.5%; HR 1.27, 95% CI 1.07–1·50; P = 0.0086) and all-cause death (6.6% vs. 6.7%; HR 1.16, 95% CI 1.03–1.32; P = 0.025). In combined analyses of the three trials, risks of future events were significantly higher in participants with both residual inflammatory risk and cholesterol risk (hs-CRP ≥2 mg/L and LDL-C ≥ 70 mg/dL, respectively) than in participants with neither residual inflammatory risk nor residual cholesterol risk (hs-CRP <2 mg/L and LDL-C < 70 mg/dL; all P values <0.0001). Risks of events were significantly higher in participants with hs-CRP ≥2 mg/L than in those with hs-CRP <2 mg/L, irrespective of LDL-C strata (all P values ≤0.0001). These effects were particularly strong for cardiovascular death and all-cause death. Lipid lowering is the cornerstone of prevention of atherosclerosis and its complications.2 However, cardiovascular events continue to occur frequently, even among individuals who achieve guideline-recommended LDL-C levels in response to lifestyle interventions and pharmacological treatments. In addition to aggressive LDL-C reduction and blood pressure control, efforts to target residual cardiovascular risk have focused on addressing systemic inflammation, hypertriglyceridaemia, platelets, and coagulation pathways.3 Inflammation plays multiple roles in the progression and destabilization of atherosclerotic disease. Nowadays, virtually all atherosclerotic patients are treated with statins, which lower both LDL-C and hs-CRP levels. Nevertheless, three randomized trials have shown that targeted anti-inflammatory therapy with canakinumab (which inhibits the interleukin-1β inflammatory pathway) or low-dose colchicine can significantly reduce cardiovascular event rates among patients with recent myocardial infarction or chronic coronary disease receiving statins in the absence of any reduction in LDL-C.4–7 Multiple agents beyond canakinumab and colchicine are being considered or are under active investigation in atherosclerotic disease trials, including upstream direct NLRP3 antagonists and downstream interleukin-6 inhibitors.3 Targeting inflammation in patients with or at high risk for ASCVD may require more individualized approaches than were needed for other risk factors.8 Moreover, as trials consistently show that further reductions in cardiovascular risk can be achieved with add-on lipid-lowering therapies in addition to statins, such as ezetimibe, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and inclisiran, most clinical guidelines worldwide have appropriately endorsed the notion that lower LDL-C is better.9 In the current analyses among patients receiving intensive statin therapy, the strength of the associations of residual inflammatory risk with cardiovascular events and mortality appeared to be greater than that of residual cholesterol risk.1 Advantages of this collaborative analysis were the large sample size that conferred sufficient statistical power to investigate associations between biomarkers and cardiovascular outcomes and the use of data from three contemporary trials in which all participants received intensive guideline-directed medical therapy. Within each trial, there were consistent biomarker measurements, accurate validation of patient characteristics and outcomes, and minimal loss to follow-up, thus reducing information and selection bias. The authors explicitly chose three trials that focused on triglyceride lowering to avoid settings in which either LDL-C or hs-CRP was a primary selection criterion for cohort recruitment, a limitation that occurred in previous studies comparing the prevalence of residual cholesterol risk and residual inflammatory risk in the setting of ezetimibe or PCSK9 inhibition.3 However, caution should be exercised in interpreting these results. First of all, association does not necessarily imply causation. Moreover, high-intensity statin use and diabetes are known confounders for the associations between cholesterol, inflammation, and cardiovascular events; however, Cox’s multivariable models did not account for these factors. Effect modification according to primary vs. secondary prevention was also not investigated. A further important issue is related to comparing HRs between separate Cox models for LDL-C and hs-CRP instead of comparing both in the same prediction model. Finally, residual inflammatory risk may appear to be more important than residual cholesterol risk in this analysis because patients were already receiving intensive statin therapy in the included trials. Surprisingly, a relatively modest increase in the risk of MACEs by moving from the lowest to the highest quartile of hs-CRP was associated with a substantial increase in mortality, whereas reducing hs-CRP with existing anti-inflammatory agents appears to produce appreciable reductions in MACEs without changing mortality.4–7 On the other hand, moving from the lowest to the highest quartile of LDL-C had no detectable effect on MACEs, whereas we know from phase 3 studies of PCSK9-inhibitors that further reducing LDL-C by ∼50%–60% does have a measurable impact on MACEs.10,11 Nevertheless, these findings are of potential clinical relevance. First, in secondary prevention, clinicians can measure hs-CRP along with LDL-C levels if they wish to understand the residual risks faced by their patients. Second, these data should not be interpreted as diminishing the critical role of lipid-lowering agents other than statins for patients with persistent or refractory hypercholesterolaemia but suggest that targeting LDL-C alone may not completely mitigate atherosclerotic risk, while anti-inflammatory treatment might provide incremental CV benefits. However, at present, most cardiologists are probably not yet ready to treat patients with ASCVD with a combination of lipid-lowering agents and anti-inflammatory drugs (essentially, low-dose colchicine), as the long-term risk-benefit profile of anti-inflammatory drug therapy has not been properly defined. The relatively short duration of both COLCOT5 and LoDoCo26 (23 and 29 months, respectively) is largely inadequate to assess the long-term safety of colchicine for secondary prevention of ASCVD.12 We clearly need to find more specific targets for cardiovascular inflammation to be tested in long-term clinical trials designed to enrol patients undergoing accurate immune phenotyping.8 No new data were generated or analysed in support of this research.